Last reviewed · How we verify
controlled-release oxycodone
At a glance
| Generic name | controlled-release oxycodone |
|---|---|
| Also known as | Opioid, Postoperative analgesia, Postoperative pain, CRO |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy (PHASE3)
- Opioid-Sparing Joint Replacement (PHASE3)
- Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery (NA)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Opioid Use After Laparoscopic Salpingectomy (PHASE4)
- Post-Op Pain Control for Prophylactic Intramedullary Nailing. (PHASE3)
- NSAID Use After Robotic Partial Nephrectomy (PHASE2)
- Hip Arthroscopy Postoperative Opioid Demands (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- controlled-release oxycodone CI brief — competitive landscape report
- controlled-release oxycodone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI